This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
HOLX vs. COO: Which GYN Surgical Stock Is the Better Investment Now?
by Moumi Mondal
As demand for GYN surgical tools climbs, HOLX and COO battle it out. Find out which stock shows stronger growth momentum now.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic (HOLX) Suffers a Larger Drop Than the General Market: Key Insights
by Zacks Equity Research
Hologic (HOLX) concluded the recent trading session at $64.14, signifying a -1.6% move from its prior day's close.
Hologic's Margin Stability Amid Tariffs: What's Behind the Confidence?
by Moumi Mondal
HOLX lifts margins despite tariffs and weak China sales, leaning on diagnostics strength and high-margin buys.
Can Hologic Lean on Its Strengths in a Tough Macroeconomic Climate?
by Moumi Mondal
HOLX grapples with global headwinds, but growth in Diagnostics and Breast Health service lifts confidence.
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
by Zacks Equity Research
Zacks.com users have recently been watching Hologic (HOLX) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hologic Climbs 13% in a Month: How Should You Play the Stock?
by Moumi Mondal
HOLX up 13% over the last month, supported by a rejected $16.7 billion buyout offer and new BCI data. What's the investment outlook?
Hologic Navigates Breast Health Slump: Is the Growth Thesis Intact?
by Zacks Equity Research
HOLX weathers Breast Health softness with rising service revenues, the Endomag acquisition and new tech on the horizon.
Here is What to Know Beyond Why Hologic, Inc. (HOLX) is a Trending Stock
by Zacks Equity Research
Hologic (HOLX) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
HOLX vs. DGX: Which Women's Health-Focused Stock Is the Better Pick?
by Moumi Mondal
The women's health market is booming, with Hologic and Quest Diagnostics leading the charge. But which one stands out more for investors today?
Is Trending Stock Hologic, Inc. (HOLX) a Buy Now?
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Understanding Hologic (HOLX) Reliance on International Revenue
by Zacks Equity Research
Evaluate Hologic's (HOLX) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Tariffs Dim Hologic's 2025 Expectations: Time to Reassess the Stock?
by Moumi Mondal
HOLX displays cautious fiscal 2025 guidance in a challenging geopolitical and macroeconomic environment. What does it mean for the stock?
Hologic, Inc. (HOLX) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.
Hologic Q2 Earnings & Revenues Top, '25 EPS View Lowered, Stock Down
by Zacks Equity Research
HOLX delivers earnings and revenue beat in the second quarter of fiscal 2025 amid macroeconomic turbulence.
Hologic (HOLX) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Hologic (HOLX) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Hologic (HOLX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Hologic (HOLX) delivered earnings and revenue surprises of 0.98% and 0.34%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Accuray (ARAY) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Accuray (ARAY) delivered earnings and revenue surprises of 80% and 10.86%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Watch These 3 MedTech Stocks This Earnings Season: Beat or Miss?
by Moumi Mondal
MedTech bigwigs, such as CVS, HOLX and IDXX, are set to post their quarterly results tomorrow. Can they deliver on expectations?
Insights Into Hologic (HOLX) Q2: Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
GYN Surgical Division Likely to Drive Hologic's Q2 Earnings
by Zacks Equity Research
HOLX's second-quarter fiscal 2025 performance is likely to have benefited from expanding breast health offerings.
Hologic Set to Report Q2 Earnings: Buy, Sell or Hold the Stock?
by Moumi Mondal
Molecular Diagnostics is likely to have aided HOLX's performance in the second quarter of fiscal 2025.
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Hologic vs. MYGN: Which Molecular Diagnostics Player Has More Upside?
by Moumi Mondal
Both HOLX and Myriad Genetics are longstanding key players in the Molecular Diagnostics space. But which one is a better investment now?
Hologic (HOLX) Stock Moves -1.08%: What You Should Know
by Zacks Equity Research
In the most recent trading session, Hologic (HOLX) closed at $56.94, indicating a -1.08% shift from the previous trading day.